Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

New Strategies to Protect Cancer Patients From Serious Treatment-Related Infection

January 1, 1998
Publication
Article
OncologyONCOLOGY Vol 12 No 1
Volume 12
Issue 1

Researchers presented new strategies to protect patients from life-threatening infections caused by dose-intensive anticancer therapy at a symposium held in conjunction with the 39th Annual Meeting of the American Society of Hematology (ASH).

Researchers presented new strategies to protect patients from life-threatening infections caused by dose-intensive anticancer therapy at a symposium held in conjunction with the 39th Annual Meeting of the American Society of Hematology (ASH).

The strategies focus on preserving the normal “barrier” function of the cells that line the gastrointestinal tract in patients undergoing high-dose chemotherapy and radiation therapy regimens.

The symposium was sponsored by the Emory University School of Medicine and was supported, in part, through an unrestricted grant from Cell Therapeutics, Inc.

According to Rein Saral, MD, professor of medicine at Emory University School of Medicine and chair of the session, infection is a major source of death and morbidity in cancer patients. Serious and fatal infections can occur as a result of two major side effects:

  • A breakdown of the mucosal barrier in the gastrointestinal tract sets the stage for infectious microorganisms to enter the otherwise sterile bloodstream.

  • Neutropenia weakens the body’s immune system.

Dr. Saral said that in some patients, particularly those whose immune system has been compromised by intensive chemotherapy, infection can often be deadly. In others, chemotherapy or radiation treatment is stopped prematurely or inadequate treatment doses are given because physicians fear the risk of infection.

“Barrier dysfunction from chemotherapy and radiation occurs quickly but is not immediately detectable,” Dr. Saral said. Infections and mucositis occur after the barrier has failed, making treatment of infection difficult because the organisms have already entered the bloodstream, he said.

Mitchell P. Fink, MD, surgeon-in-chief at the Beth Israel Deaconess Medical Center and professor of surgery at Harvard Medical School, identified chemotherapy and radiation as major causes of injury to the gastrointestinal barrier and suggested that infection was a biological consequence of barrier injury.

Current Treatments Address Only Part of the Problem

Eric J. Bow, MD, MSc, associate professor of medicine and medical microbiology and head of the Section of Hematology and Oncology at the University of Manitoba, Canada, suggested that current strategies to treat infection in patients undergoing anticancer therapy, including growth factors to treat neutropenia, only address part of the problem.

“Oncologists and hematologists typically regard fever as a marker of infection,” Dr. Bow said. “However, we are learning that many of the unexplained fevers in neutropenic patients may not be due to infection but rather to inflammatory products which have translocated from the gastrointestinal tract into the bloodstream.”

Dr. Bow said a recent review of 110 patients undergoing chemotherapy for acute myeloid leukemia (AML) revealed that progressive damage to the epithelial surface of the gastrointestinal tract correlated with a risk of invasive infection, independent of neutropenia. The study, which was published in the June 1997 Journal of Clinical Oncology, suggested that:

  • Gastrointestinal barrier failure occurs early after chemotherapy and before the onset of neutropenia.
  • The presence of bloodborne infection correlates with gastrointestinal damage measurements and not fever or neutropenia.
  • Shortening the duration of febrile neutropenia with growth factors has not had an effect on serious infection or patient outcome.

Dr. Bow suggested that therapies that attack both barrier dysfunction and neutropenia may better address the problem of therapy-induced infection.

Barrier Dysfunction and Lipids

According to Dr. Bow, one pharmacologic agent under development, lisofylline, may help preserve normal barrier function by regulating the production of inflammatory mediators, such as hydroperoxides. When exposed to chemotherapy and radiation, these mediators are biochemically altered to form lipid peroxides, a reactive lipid species believed to disrupt cell membranes and ultimately cause damage or death of cells lining the gastrointestinal tract. The oxidized lipids also may have an indirect effect on stress-activated pathways, which may result in inflammation of tissue and delayed healing.

Dr. Bow presented research that described a correlation between the breakdown of the gastrointestinal barrier and the presence of elevated levels of a subset of biologically reactive oxidized lipids, hydroperoxyoctadecadienoic acids (HPODEs), in patients undergoing chemotherapy.

Earlier studies indicated that lisofylline decreases elevated HPODE levels and prevents the rise in levels of oxidized lipids that occurs following exposure to radiation and/or chemotherapy, and that these changes correlate with a reduction in toxicity and mortality following allogeneic bone marrow transplantation.

New Research on Mucositis

Stephen T. Sonis, DMD, DMSc, professor and chairman of the department of oral medicine and diagnostic science at Harvard Medical School and a leading expert on mucositis, described early studies in animals suggesting that lisofylline may limit the severity of ulcerative mucositis induced by chemotherapy and decrease the incidence of mucositis induced by radiation.

According to Dr. Sonis, a preliminary review of data from a recently completed study indicated that high-dose lisofylline favorably affects the severity of ulcerative mucositis induced by cytarabine. In another study, administration of standard or low doses of lisofylline immediately prior to and during radiation was dramatically protective, with treated patients never developing frank ulcerations. Consistent with these findings, lisofylline-treated animals thrived throughout the course of the experiment, gaining weight in comparison to a control group.

Dr. Sonis, who also serves as chief of oral medicine, oral maxillofacial surgery and dentistry at Brigham & Women’s Hospital, Boston, said that mucositis occurs to some extent in about 40% of patients receiving chemotherapy and in virtually all patients who undergo radiation therapy for cancers of the head and neck, and yet researchers are just beginning to understand its complex biological basis.

“When patients are exposed to chemotherapy or radiation, initially there is an outpouring of cytokines. This, in turn, prompts aggressive inflammation and tissue injury,” Dr. Sonis said. “At the same time, the cells in the oral cavity break down, causing the tissue to thin, allowing ulcers to form in the mouth.”

The mouth ultimately loses its ability to function as a barrier to bacteria and fungi, thus putting the patient at risk of systemic infection, Dr. Sonis explained. In addition, ulcers are colonized by bacteria, resulting in localized secondary infections, which can prompt additional inflammation. Patients treated with chemotherapy, which suppresses the immune system, also are at risk for secondary local and distant infection and septicemia.

New Approaches Needed

Dr. Saral suggested that novel approaches to preventing barrier disruption and subsequent infection could play a key role in more effectively protecting cancer patients from serious and fatal infections.

“Despite existing strategies to treat patients who develop infection as a result of anticancer therapy, substantial morbidity and mortality from infectious complications still occur in this patient population. Therefore, more effective measures are needed to prevent potentially infectious microorganisms in the gastrointestinal tract from traveling across the mucosal barrier and entering the bloodstream,” Dr. Saral said. 

Articles in this issue

Small-Cell Lung Cancer: Is There a Standard Therapy?
Recent Advances With Chemotherapy for NSCLC: The ECOG Experience
Overcoming Drug Resistance in Lung Cancer
Paclitaxel, Carboplatin, and Radiation Therapy for Non-Small-Cell Lung Cancer
Paclitaxel, Carboplatin, and Extended-Schedule Oral Etoposide for Small-Cell Lung Cancer
Paclitaxel/Carboplatin in the Treatment of Non-Small-Cell Lung Cancer
The Role of Carboplatin in the Treatment of Small-Cell Lung Cancer
Issues in Nonoperative Management of Locally Advanced Non-Small-Cell Lung Cancer
Future Directions in Non-Small-Cell Lung Cancer: A Continuing Perspective
The Role of Prognostic Factors and Oncogenes in the Detection and Management of Non-Small-Cell Lung Cancer
Prophylactic Cranial Irradiation in Small-Cell Lung Cancer: Is It Ever Indicated?
Continuing Controversies in Staging NSCLC: An Analysis of the Revised 1997 Staging System
Small-Cell Lung Cancer: A Perspective on the Past and a Preview of the future
Integrating Thoracic Radiotherapy in the Treatment of Limited Small-Cell Lung Cancer
One-Hour Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
Related Content

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Ariana Pelosci
July 25th 2025
Article

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Tim Cortese
July 25th 2025
Article

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

Related Content

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Ariana Pelosci
July 25th 2025
Article

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Tim Cortese
July 25th 2025
Article

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.